Search clinical trials for: Placebo to match FF/UMEC/VI

Total 210 results

GlaxoSmithKline

Recruiting

A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

Asthma

United States
GlaxoSmithKline

Recruiting

Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma

Asthma

China
GlaxoSmithKline
Parexel

Completed

A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Chile, Romania, Canada
GlaxoSmithKline
Parexel

Completed

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Poland, United States, Russian Federation
GlaxoSmithKline

Completed

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2

Pulmonary Disease, Chronic Obstructive

Germany, United States, Korea, Republic of, Czech Republic
GlaxoSmithKline

Completed

A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Romania, Russian Federation, Ukraine, Germany, Hungary, Bulgaria
GlaxoSmithKline

Completed

Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Germany, Poland, Romania, Russian Federation, Ukraine
GlaxoSmithKline

Completed

A Phase I Pharmacokinetic Study of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 Microgram [mcg]) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese Subjects

Pulmonary Disease, Chronic Obstructive

China
GlaxoSmithKline

Completed

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, United States, Netherlands, Czechia
GlaxoSmithKline

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

India
GlaxoSmithKline

Completed

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Czechia
GlaxoSmithKline

Completed

To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD

Pulmonary Disease, Chronic Obstructive

China
GlaxoSmithKline

Completed

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

Asthma

Australia, United States, Argentina, Canada, Germany, Japan, Korea, Republic of, Romania, Russian Federation, Spain, South Africa, Netherlands, Poland, Italy, United Kingdom
GlaxoSmithKline

Completed

A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Poland, Romania, Russian Federation, Ukraine, Bulgaria, Estonia, Mexico, Korea, Republic of, Slovakia, Greece, China, Italy, Hungary, Czechia
Dr. Grace Parraga
GlaxoSmithKline

Active, not recruiting

Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma (ETHA)

Asthma

Canada
GlaxoSmithKline

Completed

Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Australia, Argentina, Japan, Russian Federation, Spain, Germany, Mexico, Romania, Korea, Republic of, Poland, Italy, France
GlaxoSmithKline

Completed

INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design

Pulmonary Disease, Chronic Obstructive

Germany, Spain, Netherlands, Sweden, United Kingdom
GlaxoSmithKline
Q2 Solutions; York Bioanalytical Solution; BI Medical.Inc; SRL Mediserch.Inc; Parexel...

Completed

A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma

Asthma

Japan
GlaxoSmithKline

Completed

Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response

Asthma

United Kingdom, Germany, New Zealand
AstraZeneca

Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Inhaled AZD8683

Healthy

United Kingdom
CoMentis
Alpharmagen, Inc.

Suspended

Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia

Schizophrenia

United States
AstraZeneca

Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594

Pharmacokinetics | Safety | Pharmacodynamics of AZD7594

United Kingdom
GlaxoSmithKline

Completed

A Study to Assess the Bronchodilator Effect of a Single Dose of Fluticasone Furoate (FF)/ Vilanterol (VI) 100/25 Micrograms (mcg) Combination When Administered in Adult Patients With Asthma

Asthma

New Zealand
Pierre Fabre Medicament
European Organisation for Research and Treatment of Cancer - EORTC

Active, not recruiting

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)

Melanoma

Spain, Canada, Hungary, Italy, Belgium, Netherlands, Australia, Czechia, Greece, Brazil, Portugal, Serbia, Sweden, Norway, Germany, Argentina, Romania, Poland, United Kingdom, Austria, Switzerland, France, South Africa
Novartis Pharmaceuticals

Active, not recruiting

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD (Lp(a)HORIZON)

Cardiovascular Disease and Lipoprotein(a)

China, Germany, United States, South Africa, Italy, Spain, Belgium, Czechia, Hungary, Japan, Taiwan, Netherlands, Australia, Austria, Canada, France, Israel, Switzerland, United Kingdom, Korea, Republic of, Argentina, Denmark, Greece, Romani... and more
AstraZeneca

Completed

AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients

Multiple System Atrophy, MSA

United States, Finland, Austria, France, Sweden, United Kingdom, Italy
AstraZeneca

Completed

The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

Schizophrenia

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

China
Xencor, Inc.
PPD; ICON plc

Completed

A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States
AstraZeneca
Quintiles, Inc.

Completed

This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects

Healthy

United States
HighTide Biopharma Pty Ltd

Completed

A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia

Hypercholesterolemia

Australia
Lohocla Research Corporation
National Institute on Drug Abuse (NIDA)

Recruiting

A Study to Test the Effects of Kindolor at Different Doses in Healthy Adults

Chronic Pain

United States
GlaxoSmithKline

Recruiting

Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection

Hepatitis B

United Kingdom
GlaxoSmithKline

Completed

A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease

Alzheimer's Disease

Australia, Sweden, Norway
GlaxoSmithKline

Completed

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Puerto Rico, United States, Australia, Argentina, France, Germany, Japan, Netherlands, Russian Federation, Spain, Ukraine, Finland, Czechia, Poland, Belgium, Chile, Peru, South Africa, Sweden, Thailand, Israel, Korea, Republic of, C... and more
Medicines for Malaria Venture
Q-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer...

Completed

Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A

Malaria

Australia
Desentum Oy

Completed

Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants

Birch Pollen Allergy

Canada
Boehringer Ingelheim

Terminated

A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is

Psoriasis

United States, Canada, Germany
Gilead Sciences

Completed

Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator (TEMPO)

Ventricular Arrhythmia

Netherlands, Israel, United States, Denmark, Canada, Germany, Czechia, Hungary, Poland
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (ATLAS)

Nonalcoholic Steatohepatitis

Hong Kong, United States, Australia, Puerto Rico, New Zealand, Canada
SIGA Technologies
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers (SIGA-246-002)

Healthy

United States
Fujian Akeylink Biotechnology Co., Ltd.

Recruiting

A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B

Chronic Hepatitis B

China
Desentum Oy

Completed

Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy

Birch Pollen Allergy

Finland
Gilead Sciences

Terminated

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis (PBC-Phase 2)

Primary Biliary Cholangitis

United States, Canada, Austria, United Kingdom
Gilead Sciences

Completed

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

Primary Sclerosing Cholangitis

United States, Canada, United Kingdom, Austria
Novaremed Ltd.

Completed

Effect of NRD135S.E1 in Peripheral Neuropathic Pain in Diabetic Patients

Diabetic Peripheral Neuropathic Pain

Israel
Lassen Therapeutics 1 PTY LTD

Recruiting

A Study to Evaluate the Safety and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease

Thyroid Eye Disease | Pulmonary Fibrosis

Australia, Hong Kong, New Zealand
Gilead Sciences
Galapagos NV

Completed

Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease (Divergence2)

Fistulizing Crohn's Disease

United States, Italy, Belgium, Austria, Canada, Hungary, United Kingdom, Germany, France

3

Subscribe